Ignite Creation Date:
2024-05-05 @ 10:01 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00004669
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
2000-02-24
Brief Title:
Phase II Pilot Study of Early Cortisol Replacement to Prevent Bronchopulmonary Dysplasia
Sponsor:
National Center for Research Resources NCRR
Organization:
Office of Rare Diseases ORD
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2001-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
OBJECTIVES I Estimate the efficacy of cortisol replacement therapy during the first 12 days of life for prevention of bronchopulmonary dysplasia
II Estimate the effect of cortisol replacement therapy on the signs of acute adrenal insufficiency
III Evaluate the effects of cortisol replacement therapy on adrenal hormone concentrations and on the ability of the adrenal gland to respond to ACTH
IV Determine the effect of this replacement therapy on markers of inflammation in lung lavage fluid and peripheral blood leukocytes
II Estimate the effect of cortisol replacement therapy on the signs of acute adrenal insufficiency
III Evaluate the effects of cortisol replacement therapy on adrenal hormone concentrations and on the ability of the adrenal gland to respond to ACTH
IV Determine the effect of this replacement therapy on markers of inflammation in lung lavage fluid and peripheral blood leukocytes
Detailed Description:
PROTOCOL OUTLINE This is a randomized double blind placebo controlled study Hydrocortisone therapy IV or placebo begins no later than 48 hours after birth and continues every 12 hours for 12 days Hydrocortisone is given at 2-4 times the basal cortisol secretion rate
Tracheal lavage on intubated babies is performed at start of study and on day 4 of life to assess concentrations of inflammatory markers
If larger babies show appropriate response to ACTH by 15-17 days and the less mature babies show a decreased response then a longer course of therapy is proposed for future studies
Tracheal lavage on intubated babies is performed at start of study and on day 4 of life to assess concentrations of inflammatory markers
If larger babies show appropriate response to ACTH by 15-17 days and the less mature babies show a decreased response then a longer course of therapy is proposed for future studies
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| PENN-420633 | None | None | None |